Global Enzyme Replacement Therapy Market Size, Trends, and Growth Opportunity, By Enzyme Type (Alglucerase alfa, Imiglucerase, Taliglucerase alfa, Velaglucerase alfa, Others), By Indication Type (Gaucher Disease, Fabry Disease, Pompe Disease, Hurler Syndrome, Others), By Route of Administration (Oral, Injectable, Others), By End Users (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East) and Forecast till 2030.
Global Enzyme Replacement Therapy Market
The Global Enzyme Replacement Therapy Market was valued at USD 12.34 billion in 2022 and is expected to expand to USD 22.54 billion in 2030 at a CAGR of 6.77% during the forecast period 2023-2030.
Enzyme replacement therapy" refers to treatment that utilizes human, animal or a recombinantly designed enzyme to treat congenital enzyme deficiencies. It involves a replacement of artificial enzymes in people having enzyme deficiency.
Market Drivers
The growing incidences of rare, chronic, inherited diseases along with various kinds of lysosomal storage diseases and genetic diseases propel the growth of the market.
The rising adoption, growing population, and rise in availability of enzyme replacement therapies act as major factors for the growing market during the forecast period. Furthermore, the increasing awareness among people and growing healthcare infrastructure facilities boost the expansion of the market.
The rising advancement in enzyme replacement therapy and growing government support fuels market growth.
Market Restraints
The lack of skilled professionals available for enzyme replacement therapy and the side effects associated with therapy hinders the growth of the market.
Furthermore, the availability of alternative therapies over enzyme replacement therapies restrains the growth of the global enzyme replacement therapy market.
COVID-19 Impact on the Enzyme Replacement Therapy Market
The outbreak of covid-19 positively impacted the market as the rising demand for enzyme replacement therapy to prevent and overcome the risk of developing covid-19. The various guidelines and safety precautions followed in various hospitals and infusion centers to treat novel diseases during a pandemic.
The growing initiatives by healthcare authorities regarding self-administration and growing government support have driven the enzyme replacement therapy market.
Impact of Russia Ukraine War on the Market
The conflict between Russia and Ukraine can have both direct and indirect impacts on the enzyme replacement therapy market:
Disruptions in the supply chain: Many enzyme replacement therapy manufacturers source components from Russia and Ukraine. The war may cause supply chain disruptions and delays, affecting enzyme replacement therapy production and delivery.
Economic sanctions: Economic sanctions imposed on Russia may have an impact on the overall economy, as well as the demand for enzyme replacement therapy in the region.
Market Segmentation
The Global Enzyme Replacement Therapy Market is segmented based on Enzyme Type, Indication Type, Route of Administration, End Users, Distribution Channel, and Region. Based on Enzyme Type, it is segmented into Alglucerase Alfa, Imiglucerase, Taliglucerase Alfa, Velaglucerase Alfa, and Others. On the basis of Indication Type, it is segmented into Gaucher Disease, Fabry Disease, Pompe Disease, Hurler Syndrome, and Others. Based on the Route of Administration, it is segmented into Oral, Injectable, and Others. Based on End Users, it is segmented into Hospitals, Homecare, Specialty Clinics, and Others. On the basis of the Distribution Channel, it is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others. On the basis of Region, it is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Regional Analysis
North America is likely to dominate the market over the forecast period owing to the rapid advancement in healthcare facilities and growing demand for treatment options for rare diseases driven by the market in this region. Furthermore, the rising incidences of lysosomal storage disorder fuel the market.
Asia Pacific is also anticipated to witness substantial growth because of the rising population and rising government initiatives regarding awareness of therapy in this region.
Key Players
Various key players are listed in this report such as CANbridge Life Sciences Ltd, Leadiant Biosciences Inc, TEIJIN LIMITED, Avid Bioservices Inc, SmartPharm Therapeutics, GREEN CROSS CORP, GlaxoSmithKline plc, Alexion Pharmaceuticals Inc, Horizon Therapeutics plc, Actelion Pharmaceuticals Ltd, Protalix Biotherapeutics, AbbVie Inc, Johnson & Johnson Services Inc, Digestive Care Inc, Takeda Pharmaceutical Company Limited, and Perseo Pharma AG.
Market Taxonomy
By Enzyme Type
• Alglucerase Alfa,
• Imiglucerase
• Taliglucerase Alfa
• Velaglucerase Alfa
• Others
By Indication Type
• Gaucher Disease
• Fabry Disease
• Pompe Disease
• Hurler Syndrome
• Others
By Route of Administration
• Oral
• Injectable
• Others
By End Users
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Distribution Channel
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others
By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
Key Question Addressed by the Report
• What are the Key Opportunities in the Global Enzyme Replacement Therapy Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have the highest growth?
• What are the factors that will impact/drive the Market?
• What is the role of key players in the value chain?
Global Enzyme Replacement Therapy Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Source
3 Executive Summary
4 Global Enzyme Replacement Therapy Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn
4.2.6 Post covid-19 world Supply& Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Enzyme Replacement Therapy Market, By Enzyme Type
5.1 Y-o-Y Growth Comparison, By Enzyme Type
5.2 Global Enzyme Replacement Therapy Market Share Analysis, By Enzyme Type
5.3 Global Enzyme Replacement Therapy Market Size and Forecast, By Enzyme Type
5.3.1 Alglucerase alfa
5.3.2 Imiglucerase
5.3.3 Taliglucerase alfa
5.3.4 Velaglucerase alfa
5.3.5 Others
6 Global Enzyme Replacement Therapy Market, By Indication Type
6.1 Y-o-Y Growth Comparison, By Indication Type
6.2 Global Enzyme Replacement Therapy Market Share Analysis, By Indication Type
6.3 Global Enzyme Replacement Therapy Market Size and Forecast, By Indication Type
6.3.1 Gaucher Disease
6.3.2 Fabry Disease
6.3.3 Pompe Disease
6.3.4 Hurler Syndrome
6.3.5 Others
7 Global Enzyme Replacement Therapy Market, By Route of Administration
7.1 Y-o-Y Growth Comparison, By Route of Administration
7.2 Global Enzyme Replacement Therapy Market Share Analysis, By Route of Administration
7.3 Global Enzyme Replacement Therapy Market Size and Forecast, By Route of Administration
7.3.1 Oral
7.3.2 Injectable
7.3.3 Others
8 Global Enzyme Replacement Therapy Market, By End Users
8.1 Y-o-Y Growth Comparison, By End Users
8.2 Global Enzyme Replacement Therapy Market Share Analysis, By End Users
8.3 Global Enzyme Replacement Therapy Market Size and Forecast, By End Users
8.3.1 Hospitals
8.3.2 Homecare
8.3.3 Specialty Clinics
8.3.4 Others
9 Global Enzyme Replacement Therapy Market, By Distribution Channel
9.1 Y-o-Y Growth Comparison, By Distribution Channel
9.2 Global Enzyme Replacement Therapy Market Share Analysis, By Distribution Channel
9.3 Global Enzyme Replacement Therapy Market Size and Forecast, By Distribution Channel
9.3.1 Hospital Pharmacy
9.3.2 Online Pharmacy
9.3.3 Retail Pharmacy
9.3.4 Others
10 Global Enzyme Replacement Therapy Market, By Region
10.1 Global Enzyme Replacement Therapy Market Share Analysis, By Region
10.2 Global Enzyme Replacement Therapy Market Share Analysis, By Region
10.3 Global Enzyme Replacement Therapy Market Size and Forecast, By Region
11 North America Enzyme Replacement Therapy Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 North America Enzyme Replacement Therapy Product Market Share Analysis, By Enzyme Type
11.3 North America Enzyme Replacement Therapy Product Market Size and Forecast, By Indication Type
11.4 North America Enzyme Replacement Therapy Product Market Size and Forecast, By Route of Administration
11.5 North America Enzyme Replacement Therapy Product Market Size and Forecast, By End Users
11.6 North America Enzyme Replacement Therapy Product Market Size and Forecast, By Distribution Channel
11.7 North America Enzyme Replacement Therapy Product Market Size and Forecast, By Country
11.7.1 U.S.
11.7.2 Canada
11.7.3 Mexico
12 Europe Enzyme Replacement Therapy Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Europe Enzyme Replacement Therapy Product Market Share Analysis, By Enzyme Type
12.3 Europe Enzyme Replacement Therapy Product Market Size and Forecast, By Indication Type
12.4 Europe Enzyme Replacement Therapy Product Market Size and Forecast, By Route of Administration
12.5 Europe Enzyme Replacement Therapy Product Market Size and Forecast, By End Users
12.6 Europe Enzyme Replacement Therapy Product Market Size and Forecast, By Distribution Channel
12.7. Europe Enzyme Replacement Therapy Product Market Size and Forecast, By Country
12.7.1 Germany
12.7.2 France
12.7.3 UK
12.7.4. Rest of Europe
13 Asia Pacific Enzyme Replacement Therapy Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Asia Pacific Enzyme Replacement Therapy Product Market Share Analysis, By Enzyme Type
13.3 Asia Pacific Enzyme Replacement Therapy Product Market Size and Forecast, By Indication Type
13.4 Asia Pacific Enzyme Replacement Therapy Product Market Size and Forecast, By Route of Administration
13.5 Asia Pacific Enzyme Replacement Therapy Product Market Size and Forecast, By End Users
13.6 Asia Pacific Enzyme Replacement Therapy Product Market Size and Forecast, By Distribution Channel
13.7 Asia Pacific Enzyme Replacement Therapy Product Market Size and Forecast, By Country
13.7.1 China
13.7.2 Japan
13.7.3 India
13.7.4. Rest of Asia Pacific
14 Latin America Enzyme Replacement Therapy Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Latin America Enzyme Replacement Therapy Product Market Share Analysis, By Enzyme Type
14.3 Latin America Enzyme Replacement Therapy Product Market Size and Forecast, By Indication Type
14.4 Latin America Enzyme Replacement Therapy Product Market Size and Forecast, By Route of Administration
14.5 Latin America Enzyme Replacement Therapy Product Market Size and Forecast, By End Users
14.6 Latin America Enzyme Replacement Therapy Product Market Size and Forecast, By Distribution Channel
14.7 Latin America Enzyme Replacement Therapy Product Market Size and Forecast, By Country
14.7.1. Brazil
14.7.2. Rest of Latin America
15 Middle East Enzyme Replacement Therapy Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 Middle East Enzyme Replacement Therapy Product Market Share Analysis, By Enzyme Type
15.3 Middle East Enzyme Replacement Therapy Product Market Size and Forecast, By Indication Type 15.4 Middle East Enzyme Replacement Therapy Product Market Size and Forecast, By Route of Administration
15.5 Middle East Enzyme Replacement Therapy Product Market Size and Forecast, By End Users
15.6 Middle East Enzyme Replacement Therapy Product Market Size and Forecast, By Distribution Channel 15.7 Middle East Enzyme Replacement Therapy Product Market Size and Forecast, By Country
15.7.1. Saudi Arabia
15.7.2. UAE
15.7.3. Egypt
15.7.4 Kuwait
15.7.5. South Africa
16 Competitive Analysis
16.1 Competition Dashboard
16.2 Market share Analysis of Top Vendors
16.3 Key Development Strategies
17 Company Profiles
17.1 CANbridge Life Sciences Ltd
17.1.1 Overview
17.1.2 Offerings
17.1.3 Key Financials
17.1.4 Business Segment & Geographic Overview
17.1.5 Key Market Developments
17.1.6 Key Strategies
17.2 Leadiant Biosciences Inc
17.2.1 Overview
17.2.2 Offerings
17.2.3 Key Financials
17.2.4 Business Segment & Geographic Overview
17.2.5 Key Market Developments
17.2.6 Key Strategies
17.3 TEIJIN LIMITED
17.3.1 Overview
17.3.2 Offerings
17.3.3 Key Financials
17.3.4 Business Segment & Geographic Overview
17.3.5 Key Market Developments
17.3.6 Key Strategies
17.4 Avid Bioservices Inc
17.4.1 Overview
17.4.2 Offerings
17.4.3 Key Financials
17.4.4 Business Segment & Geographic Overview
17.4.5 Key Market Developments
17.4.6 Key Strategies
17.5 SmartPharm Therapeutics
17.5.1 Overview
17.5.2 Offerings
17.5.3 Key Financials
17.5.4 Business Segment & Geographic Overview
17.5.5 Key Market Developments
17.5.6 Key Strategies
17.6 GREEN CROSS CORP
17.6.1 Overview
17.6.2 Offerings
17.6.3 Key Financials
17.6.4 Business Segment & Geographic Overview
17.6.5 Key Market Developments
17.6.6 Key Strategies
17.7 GlaxoSmithKline plc
17.7.1 Overview
17.7.2 Offerings
17.7.3 Key Financials
17.7.4 Business Segment & Geographic Overview
17.7.5 Key Market Developments
17.7.6 Key Strategies
17.8 Alexion Pharmaceuticals Inc
17.8.1 Overview
17.8.2 Offerings
17.8.3 Key Financials
17.8.4 Business Segment & Geographic Overview
17.8.5 Key Market Developments
17.8.6 Key Strategies
17.9 Horizon Therapeutics plc
17.9.1 Overview
17.9.2 Offerings
17.9.3 Key Financials
17.9.4 Business Segment & Geographic Overview
17.9.5 Key Market Developments
17.9.6 Key Strategies
17.10 Actelion Pharmaceuticals Ltd
17.10.1 Overview
17.10.2 Offerings
17.10.3 Key Financials
17.10.4 Business Segment & Geographic Overview
17.10.5 Key Market Developments
17.10.6 Key Strategies
17.11 Protalix Biotherapeutics
17.11.1 Overview
17.11.2 Offerings
17.11.3 Key Financials
17.11.4 Business Segment & Geographic Overview
17.11.5 Key Market Developments
17.11.6 Key Strategies
17.12 AbbVie Inc
17.12.1 Overview
17.12.2 Offerings
17.12.3 Key Financials
17.12.4 Business Segment & Geographic Overview
17.12.5 Key Market Developments
17.12.6 Key Strategies
17.13 Johnson & Johnson Services Inc
17.13.1 Overview
17.13.2 Offerings
17.13.3 Key Financials
17.13.4 Business Segment & Geographic Overview
17.13.5 Key Market Developments
17.13.6 Key Strategies
17.14 Digestive Care Inc
17.14.1 Overview
17.14.2 Offerings
17.14.3 Key Financials
17.14.4 Business Segment & Geographic Overview
17.14.5 Key Market Developments
17.14.6 Key Strategies
17.15 Takeda Pharmaceutical Company Limited
17.15.1 Overview
17.15.2 Offerings
17.15.3 Key Financials
17.15.4 Business Segment & Geographic Overview
17.15.5 Key Market Developments
17.15.6 Key Strategies
17.16 Digestive Care Inc
17.16.1 Overview
17.16.2 Offerings
17.16.3 Key Financials
17.16.4 Business Segment & Geographic Overview
17.16.5 Key Market Developments
17.16.6 Key Strategies
